SCHEMBL16323946

SCHEMBL16323946

Cc1[nH]nc(C2CC2)c1S(=O)(=O)N1CCC(Cc2ccc(Cl)c(F)c2)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
PROKR1 Q8TCW9 20/20 1.00
FPR2 P25090 18/20 0.80

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15548930 0.89 PROKR1 (1.00) PROKR1FPR2
SCHEMBL15548661 0.77 PROKR1 (1.00) PROKR1FPR2
SCHEMBL15549234 0.75 FPR2 (1.00) PROKR1FPR2
SCHEMBL15548951 0.72 PROKR1 (1.00) PROKR1FPR2
SCHEMBL15548803 0.72 PROKR1 (0.68) PROKR1FPR2
SCHEMBL15549433 0.70 PROKR1 (1.00) PROKR1FPR2
SCHEMBL17758787 0.69 PROKR1 (0.54) PROKR1FPR2
SCHEMBL16321611 0.68 PROKR1 (0.53) PROKR1FPR2
SCHEMBL15549192 0.67 FPR2 (1.00) PROKR1FPR2
SCHEMBL23365142 0.67 CCR3 (0.57) PROKR1FPR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10208016-B2 1-sulfonyl piperidine derivatives as modulators of prokineticin receptors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-02-19 US claimed
EP-3010900-B1 1-SULFONYL PIPERIDINE DERIVATIVES AS MODULATORS OF PROKINETICIN RECEPTORS TAKEDA PHARMACEUTICALS CO (JP) 2018-01-03 EP claimed
US-20170340621-A1 SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED GASTROINTESTINAL DISORDERS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-11-30 US claimed
EP-3218363-A1 SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED GASTROINTESTINAL DISORDERS Takeda Pharmaceutical Company Limited (JP) 2017-09-20 EP claimed
WO-2016075457-A1 SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED GASTROINTESTINAL DISORDERS TAKEDA CAMBRIDGE LIMITED (GB) 2016-05-19 WO claimed
US-20160122317-A1 1-SULFONYL PIPERIDINE DERIVATIVES AS MODULATORS OF PROKINETICIN RECEPTORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-05-05 US claimed
EP-3010900-A1 1-SULFONYL PIPERIDINE DERIVATIVES AS MODULATORS OF PROKINETICIN RECEPTORS Takeda Pharmaceutical Company Limited (JP) 2016-04-27 EP claimed
WO-2014202999-A1 1-SULFONYL PIPERIDINE DERIVATIVES AS MODULATORS OF PROKINETICIN RECEPTORS TAKEDA CAMBRIDGE LIMITED (GB) 2014-12-24 WO claimed
US-10335402-B2 Sulfonyl piperidine derivatives and their use for treating prokineticin mediated gastrointestinal disorders TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-07-02 US disclosed
US-10335402-B2 Sulfonyl piperidine derivatives and their use for treating prokineticin mediated gastrointestinal disorders TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-07-02 US disclosed
US-10308635-B2 1-sulfonyl piperidine derivatives as modulators of prokineticin receptors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-06-04 US disclosed
US-10308635-B2 1-sulfonyl piperidine derivatives as modulators of prokineticin receptors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-06-04 US disclosed
US-10208016-B2 1-sulfonyl piperidine derivatives as modulators of prokineticin receptors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-02-19 US disclosed
US-10208016-B2 1-sulfonyl piperidine derivatives as modulators of prokineticin receptors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-02-19 US disclosed
US-20160122317-A1 1-SULFONYL PIPERIDINE DERIVATIVES AS MODULATORS OF PROKINETICIN RECEPTORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-05-05 US disclosed
US-20160122317-A1 1-SULFONYL PIPERIDINE DERIVATIVES AS MODULATORS OF PROKINETICIN RECEPTORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-05-05 US disclosed
US-20160122317-A1 1-SULFONYL PIPERIDINE DERIVATIVES AS MODULATORS OF PROKINETICIN RECEPTORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-05-05 US disclosed
EP-3010900-A1 1-SULFONYL PIPERIDINE DERIVATIVES AS MODULATORS OF PROKINETICIN RECEPTORS Takeda Pharmaceutical Company Limited (JP) 2016-04-27 EP disclosed
WO-2014202999-A1 1-SULFONYL PIPERIDINE DERIVATIVES AS MODULATORS OF PROKINETICIN RECEPTORS TAKEDA CAMBRIDGE LIMITED (GB) 2014-12-24 WO disclosed
WO-2014202999-A1 1-SULFONYL PIPERIDINE DERIVATIVES AS MODULATORS OF PROKINETICIN RECEPTORS TAKEDA CAMBRIDGE LIMITED (GB) 2014-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160122317-A1 1-SULFONYL PIPERIDINE DERIVATIVES AS MODULATORS OF PROKINETICIN RECEPTORS GIPR, PROKR1, PROKR2 PROKR1 2/4885FPR2 946/4885
US-10308635-B2 1-sulfonyl piperidine derivatives as modulators of prokineticin receptors GIPR, PROKR1, PROKR2 PROKR1 2/4885FPR2 946/4885
US-10335402-B2 Sulfonyl piperidine derivatives and their use for treating prokineticin mediated gastrointestinal disorders PROKR1, PROKR2, GIPR PROKR1 1/4885FPR2 520/4885
US-20170340621-A1 SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED GASTROINTESTINAL DISORDERS PROKR1, PROKR2, GIPR PROKR1 1/4885FPR2 520/4885
US-10208016-B2 1-sulfonyl piperidine derivatives as modulators of prokineticin receptors GIPR, PROKR1, PROKR2 PROKR1 2/4885FPR2 946/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.